newsfilter
← Earnings
Earnings Releases·

Beta Bionics — Third Quarter 2026 Earnings Summary

  • Net sales rose 30% year-over-year to $35.5 million, driven by an 118% surge in Pharmacy Benefit Plan (PBP) channel revenue, while gross margin expanded 179 basis points to 57.3%.
  • Full-year 2026 revenue guidance was raised to $124–$126 million, though this includes a potential $8.5 million Q4 deferral as customers await the Mint launch, with losses widening to a $24.4 million net loss.
  • Mint received FDA clearance for a Q1 2027 commercial launch, while 3D Intelligence submissions were withdrawn for additional validation and a revised 510(k) application is planned for mid-Q4 2026.
  • The Company completed a public offering raising $161.3 million in net proceeds and announced a strategic integration with Senseonics' Eversense 365 system expected in Q4 2026.
  • Pivotal trial enrollment for iLet in adults with type 2 diabetes is complete, with a next-generation fully-closed loop algorithm trial scheduled to initiate in Q4 2026.
Company
BETA BIONICS INC
Sector
Healthcare
Industry
Medical Devices